Galunisertib, a TGFBR1 inhibitor, has been used clinically to improve the overall survival (OS) of HCC patients.[11, 12, 13, 14] Additionally, SMAD2/3 has been reported to promote the recruitment of the m6A methyltransferase complex to a subset of transcripts which were involved in early cell fate decisions, highlighting a function beyond their role in transcription.[15]. This evidence concerns the gene SMAD2 and hepatocellular carcinoma.